Clinical trials: Neoplasms, Thyroid
Advanced Solid Tumor
HEC169096 in Participants With Advanced Solid Tumors
An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics And Effectiveness Of HEC169096 In Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced…
- Trial name
- NCT05451602
- Testing
- HEC169096
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Papillary Thyroid Cancer, Follicular Thyroid Cancer
Sutent Adjunctive Treatment of Differentiated Thyroid Cancer
This study is comparing a drug called Sutent with standard of care treatment for people with advanced thyroid cancer. Because advanced thyroid cancer is becoming increasingly common and effective treatment options are limited…
- Conditions
- Papillary Thyroid Cancer, Follicular Thyroid Cancer, Differentiated Thyroid Cancer
- Trial name
- IIT Sutent (NCT00668811)
- Testing
- SU011248, Sutent
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Medstar Health Research Institute
Pancreatic Cancer, Small Bowel Cancer
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
The objective of this expanded access program is to provide ulixertinib (BVD-523) for compassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF…
- Conditions
- Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer, Melanoma
- Trial name
- NCT04566393
- Testing
- Ulixertinib (BVD-523)
- Where
- 26 sites in United States
- Sponsor
- xCures
Thyroid Cancer, Medullary, Carcinoid Tumor
18F-FDOPA PET in Neuroendocrine Tumours
Neuroendocrine tumours (NETs) are a group of neoplasms generally arising from the gastroenteropancreatic tract. They are usually slow growing, have low malignant potential, and often go unnoticed until they become metastatic.
- Conditions
- Thyroid Cancer, Medullary, Carcinoid Tumor, Pheochromocytoma, Paraganglioma
- Trial name
- NCT02431715
- Testing
- [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)
- Where
- Canada
- Sponsor
- British Columbia Cancer Agency
Differentiated Thyroid Cancer
Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer
Locally advanced thyroid cancer has a wide range of surgery, large trauma and high local recurrence rate. It is one of the main causes of death in patients with thyroid cancer.
- Trial name
- NCT05989425
- Testing
- surufatinib
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Fudan University
Thyroid Cancer
Environmental Factors and Thyroid Cancer
Thyroid cancer incidence has been steadily increasing and has nearly tripled since the 1970's in the US and worldwide. Early detection of small, papillary thyroid cancers using high quality diagnostic imaging explains only about…
- Trial name
- NCT05172921
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Metastatic Thyroid Cancer
Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition
This is a prospective interventional trial that aims to restore iodine incorporation in tumoral lesions of patients with unresectable, radioiodine-refractory thyroid cancer.
- Trial name
- ERRITI (NCT04619316)
- Testing
- Trametinib 2 MG [Mekinist], Trametinib 2 MG [Mekinist] and Dabrafenib 75 MG (2-0-2) [Tafinlar]
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- University Hospital, Essen
Bone Metastases, Thyroid Cancer
Radioiodine-avid Bone Metastases From Thyroid Cancer Without Structural Abnormality
Bone radioiodine (RAI) uptake without structural abnormality in thyroid cancer (TC) patients may be related to false positive or to microscopic foci of metastatic tissue. In such cases, outcome is reported to be excellent.
- Trial name
- NCT04141306
- Testing
- Administrative data, Clinical data, Histological data
- Volunteers
- 30 people
- Sponsor
- Hospices Civils de Lyon
Thyroid Cancer
Use of 18F-PSMA-11 PET for Detection of Lesions in Iodine Refractory Thyroid Cancers
Determine the diagnostic value of 18F-PSMA-11 in patients with iodine refractory thyroid cancer.
- Trial name
- NCT05175404
- Testing
- PET/CT scan F18-PSMA-11
- Where
- Belgium
- Volunteers
- 8 people
- Sponsor
- University Hospital, Ghent
Diarrhea, Medullary Thyroid Cancer
The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
Diarrhea in patients with MTC (Medullary Thyroid Cancer) can be debilitating and, in some cases life threatening. Findings in such patients include volume depletion, renal insufficiency, and electrolyte disorders.
- Trial name
- NCT01739634
- Testing
- CASAD
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Salient Pharmaceuticals Incorporated
Medullary Thyroid Carcinoma
Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTC
This study explores the clinical application of 68Ga-DOTA-CCK-FS PET/CT in detecting cholecystokinin-2 receptor (CCK-2R)-positive tumors, particularly medullary thyroid cancer (MTC) and other malignancies. Led by Prof.
- Trial name
- NCT07138716
- Testing
- 68Ga-DOTA-CCK-FS PET/CT
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Luo Yaping
Thyroid Nodules, Pulsed Field Ablation
Nanosecond Pulsed Field Ablation in the Management of Benign Thyroid Nodules
To observe the outcomes of nsPFA therapy to treat benign thyroid nodules.
- Trial name
- NCT07226804
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Thyroid Cancer
Anlotinib or Penpulimab in Combination With RAI for DTC
The purpose of this study is to assess the efficacy and safety of anlotinib in combination with I-131 in locally advanced/metastatic differentiated thyroid cancer.
- Trial name
- NCT04952493
- Testing
- Anlotinib hydrochloride, Sodium Iodide I 131, Penpulimab
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Peking Union Medical College Hospital
Breast Cancer, Colo-rectal Cancer
The French E3N Prospective Cohort Study
The French E3N cohort was initiated in 1990 to investigate the risk factors associated with cancer and other major non-communicable diseases in women.
- Conditions
- Breast Cancer, Colo-rectal Cancer, Parkinson Disease, Asthma
- Trial name
- E3N (NCT03285230)
- Where
- France
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Thyroid Cancer, Follicular Thyroid Cancer
Correlation Between Various Urinary Exosomal Protein Biomarkers and Pathological Manifestation in Thyroid Follicular Neoplasm: Early and Pre-operative Diagnosis of Follicular Thyroid Cancer
Thyroid cancer is the most common endocrine malignancy in the world. Generally, thyroid cancer could be divided into well-differentiated and poorly-differentiated.
- Trial name
- NCT05463107
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital
Thyroid Nodules
Study on HRQOL and Cost-effectiveness Analysis in Management of Patients With <2cm Thyroid Nodules
Ideally randomized controlled trials should be carried out to compare the cost-effectiveness between FNAC and watchful waiting but such studies are very difficult to conduct in practice because they require following up very…
- Trial name
- NCT02398721
- Testing
- Fine Needle Aspiration Cytology
- Where
- Hong Kong
- Volunteers
- 314 people
- Sponsor
- The University of Hong Kong
Thyroid Neoplasms
Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma
Phase II clinical trial assessing efficacy and toxicity of pretargeted radioimmunotherapy using anti-CEAxanti-DTPA bispecific antibody and di-DTPA-131I peptide in patients with reccurrence of medullary thyroid carcinoma (abnormal…
- Trial name
- RIT in MTC (NCT00467506)
- Testing
- bispecific antibody and di-DTPA-131I
- Where
- 11 sites in France
- Sponsor
- Nantes University Hospital
Hematological Neoplasms, Non-Hodgkin's Lymphoma
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
This is a Phase 1, open-label, multicenter, randomized, 2-stage crossover study consisting of 2 phases: Stage I - Pharmacokinetics (Bioequivalence), with an Extension Stage II - Pharmacokinetics (Food Effect) with an Extension…
- Conditions
- Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma
- Trial name
- NCT02223052
- Testing
- CC-486, Vidaza
- Where
- 10 sites in United States
- Volunteers
- 89 people
- Sponsor
- Celgene
Thyroid Cancer
Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer
To determine the efficacy and safety of Anlotinib in patients of locally advanced thyroid cancer in the neoadjuvant setting.
- Trial name
- NCT04309136
- Testing
- Anlotinib, surgery, core needle biopsy
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Fudan University
Medullary Thyroid Carcinoma
A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
Background: The combination of anti-cancer drugs vandetanib (given orally) and bortezomib (given intravenously) has not been used in humans. However, both drugs have been studied separately.
- Trial name
- NCT00923247
- Testing
- Bortezomib, Vandetanib
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)